Literature DB >> 28387630

Risk factors governing the development of cerebral vein and dural sinus thrombosis after craniotomy in patients with intracranial tumors.

Florian Gessler1, Markus Bruder1, Stephan Duetzmann1, Stephanie Tritt2, Joshua D Bernstock3, Volker Seifert1, Christian Senft1.   

Abstract

OBJECTIVE Neurosurgical intervention may increase the risk of developing cerebral vein and dural sinus thrombosis (CVT). The clinical management of CVT in postoperative patients remains unclear. This retrospective study explores the disease occurrence, associated risk factors, and outcomes in patients with tumors who developed CVT after craniotomy. METHODS A retrospective analysis and review of patient records in those who had undergone cranial tumor removal within the authors' neurosurgical department was performed. In so doing, the authors identified a cohort of patients who developed CVT postoperatively. The study included patients who presented to the department between January 2004 and December 2013. RESULTS Of 2286 patients with intracranial lesions who underwent craniotomy, 35 (1.5%) went on to develop CVT. The authors identified the semisitting position (OR 7.55, 95% CI 3.73-15.31, p < 0.001); intraoperative sinus injury (OR 1.5, 95% CI 3.57-15.76, p < 0.001); and known CVT risk factors (OR 7.77, 95% CI 2.28-21.39, p < 0.001) as predictors of CVT development. Of note, 19 patients (54.3%) had good outcomes (modified Rankin Scale Score 0-1), whereas 9 patients (25.7%) had suffered dependency or death (modified Rankin Scale Score 4-6) at last follow-up. Intracerebral hemorrhage (OR 21.27, 95% CI 1.59-285.01, p = 0.02) and delayed delivery of an intermediate dose of low-molecular-weight heparin anticoagulation (OR 24.12, 95% CI 2.08-280.13, p = 0.01) were associated with unfavorable outcomes. CONCLUSIONS Only a minority of patients undergoing craniotomy for tumor removal develop CVT, and the majority of those who do develop CVT recover well. Early administration of an intermediate dose of low-molecular-weight heparin anticoagulation might be considered once CVT is diagnosed.

Entities:  

Keywords:  CVT = cerebral vein and dural sinus thrombosis; ICH = intracerebral hemorrhage; IQR = interquartile range; ISCVT = International Study on Cerebral Vein and Dural Sinus Thrombosis; LMWH = low-molecular-weight heparin; anticoagulation; craniotomy; intracranial; mRS = modified Rankin Scale; neurosurgery; oncology; risk factors; sinus thrombosis

Mesh:

Year:  2017        PMID: 28387630     DOI: 10.3171/2016.11.JNS161871

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas.

Authors:  Florian Gessler; Peter Baumgarten; Joshua D Bernstock; Patrick Harter; Stephanie Lescher; Christian Senft; Volker Seifert; Gerhard Marquardt; Lutz Weise
Journal:  J Neurooncol       Date:  2017-05-15       Impact factor: 4.130

2.  Functional Outcomes and Postoperative Cerebral Venous Sinus Thrombosis after Translabyrinthine Approach for Vestibular Schwannoma Resection: A Radiographic Demonstration of Anatomic Predictors.

Authors:  Christina Gerges; Patrick Malloy; Nicholas Rabah; Dana Defta; Yifei Duan; Christina H Wright; Marte van Keulen; James Wright; Sarah Mowry; Cliff A Megerian; Nicholas Bambakidis
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-04

3.  Management of Posterior Fossa Tumors in Adults Based on the Predictors of Postoperative Hydrocephalus.

Authors:  Chengda Zhang; Tingbao Zhang; Lingli Ge; Zhengwei Li; Jincao Chen
Journal:  Front Surg       Date:  2022-06-01

4.  Squamous cell carcinoma of the scalp causing cortical venous thrombosis and Intraparenchymal hematoma.

Authors:  Mihir Gupta; Anudeep Yekula; Varun Sagi; Aditya Mittal; Marc S Schwartz
Journal:  eNeurologicalSci       Date:  2020-06-18

Review 5.  Cerebral venous thrombosis during the COVID-19 Pandemic: A multi-center experience.

Authors:  Ricardo A Domingo; Andres Ramos-Fresnedo; Carlos Perez-Vega; Shashwat Tripathi; Michael W Pullen; Jaime L Martinez; Young M Erben; James Meschia; Rabih G Tawk
Journal:  Clin Neurol Neurosurg       Date:  2022-04-19       Impact factor: 1.885

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.